Q3 2026 Financial Results
Showing 282 search results
Grifols increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26
Half of Spaniards are unaware that plasma can be donated separately from blood
Grifols strengthens evidence supporting the AMBAR® program in Alzheimer’s disease with real-world evidence data
Grifols signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain
Grifols announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency
Grifols increases revenue by 2.6% to €3.6 billion, and net profit by 28.7% to €227 million until June
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.